highly significantP < 0.001
Very highly significant ( P < 0.001) reductions in N-terminal pro-brain natriuretic peptide (NTproBNP) were documented in the patients randomized to levosimendan; these were accompanied by profound reductions in the risk of HF-related hospitalization (12-month cumulative hospitalization rate ≈20% vs. ≈65% in the placebo group; P < 0.001) and in the composite endpoint of all-cause mortality or HF-related hospitalization (12-month cumulative hospitalization rate ≈25% vs. ≈65% in the placebo group; P < 0.001).